A fresh round of sideways trading continues for Dexcom Inc (DXCM) Stock.

Redburn Atlantic raised the price target for the Dexcom Inc (NASDAQ:DXCM) stock to “a Neutral”. The rating was released on May 30, 2024, according to finviz. The research report from Morgan Stanley has resumed the stock to Equal-Weight, with a price target set at $131. The stock was upgraded by Raymond James, who disclosed in a research note on April 17, 2023, from Outperform to Strong Buy and set the price objective to $138. In their research brief published March 29, 2023, UBS analysts initiated the Dexcom Inc stock to Buy with a price target of $142.

The latest trade, Performances and Moving Averages give us the following Picture

The firm’s stock price fluctuated -2.51% within the last five trades and -9.13% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -1.82% in the last 6 months and -14.39% was subtracted to its value over the previous 3 months. DXCM stock is trading at a margin of -7.43%, -11.19% and 0.21% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.


As of the close of trading, DXCM deals in the Healthcare domain. The stock is trading -18.46 percent below its 52-week high and 54.90 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -5.44. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Dexcom Inc’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at 17.14 percent and the profit margin is 16.82 percent, and the company has reported a gross margin of 62.79 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $46.05 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Dexcom Inc (NASDAQ:DXCM) is 74.75. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 51.34. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 12.11 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 20.41, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.59 percent of Dexcom Inc shares are owned by insiders, and 93.74 percent are held by financial institutions. Brown Michael Jon, the EVP Chief Legal Officer at Dexcom Inc (DXCM) has sold 652 shares of firm on May 31 ’24 at a price of $119.24 against the total amount of $77744.0. In another inside trade, Dolan Matthew Vincent, EVP Strategy and Corporate Dev of Dexcom Inc (NASDAQ:DXCM) sold 2,423 shares of the firm on May 15 ’24 for a total worth of $0.31 million at a price of $126.58. An inside trade which took place on Apr 30 ’24, EVP Chief Legal Officer of Dexcom Inc Brown Michael Jon sold 629 shares of firm against total price of $79411.0 at the cost of $126.25 per share.

Most Popular

Related Posts